Dianthus Therapeutics Prices $625 Million Public Offering

Got story updates? Submit your updates here. ›

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases, announced the pricing of an upsized underwritten public offering of 7,313,582 shares of its common stock at $81.00 per share, as well as pre-funded warrants to purchase up to 402,468 shares. The aggregate gross proceeds are expected to be approximately $625 million.

Why it matters

The successful completion of this sizable public offering will provide Dianthus with significant capital to advance its pipeline of next-generation autoimmune disease treatments through clinical development and prepare for potential commercialization. As a clinical-stage biotech company, securing this level of funding is crucial to drive its research and development efforts forward.

The details

Dianthus plans to use the net proceeds from the offering to fund its clinical and preclinical development activities, commercial readiness efforts, as well as for general corporate purposes. The offering is expected to close on March 12, 2026, subject to customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,157,407 shares.

• The offering is expected to close on March 12, 2026.
• The underwriters have a 30-day option to purchase additional shares.

What’s next

The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions.